Artelo Biosciences, Inc. (ARTL) Insider Trading Activity

NASDAQ$0.9527-0.01 (-1.03%)
Market Cap
$3.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
447 of 876
Rank in Industry
260 of 505

ARTL Insider Trading Activity

ARTL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Insider Activity of Artelo Biosciences, Inc.

Over the last 12 months, insiders at Artelo Biosciences, Inc. have bought $0 and sold $0 worth of Artelo Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Artelo Biosciences, Inc. have bought $9,723 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,200 shares for transaction amount of $4,800 was made by Gorgas Gregory D. (Pres, CEO, CFO, Treas & Secr) on 2022‑08‑12.

List of Insider Buy and Sell Transactions, Artelo Biosciences, Inc.

2022-08-12PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
1,200
0.0445%
$4.00
$4,800
-27.57%
2022-08-11PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
1,200
0.0456%
$4.03
$4,836
-26.08%
2021-04-16PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
8,500
0.0366%
$1.15
$9,809
-30.80%
2020-05-15PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
4,200
0.1219%
$1.21
$5,072
-5.00%
2020-05-04PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
4,167
0.1136%
$1.20
$5,000
-9.45%
2020-05-04PurchaseMATSUI CONNIEdirector
41,667
1.1357%
$1.20
$50,000
-9.45%
2019-11-04PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,400
0.0701%
$2.21
$5,304
-45.78%
2019-11-01PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,500
0.0823%
$2.28
$5,702
-40.29%
2019-10-31PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,500
0.0729%
$1.95
$4,875
-38.19%
2019-10-30PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,600
0.0771%
$1.99
$5,186
-38.50%
2019-10-15PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,600
0.0793%
$2.05
$5,333
-37.50%
2019-10-11PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,700
0.0796%
$1.96
$5,296
-36.87%
Total: 12

Insider Historical Profitability

<0.0001%
MATSUI CONNIEdirector
56667
1.7271%
$54,762.9910
<0.0001%
Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2400
0.0731%
$2,319.36110
<0.0001%

Historical Insider Profitability vs. Competitors

$13,665,147
42
-70.74%
$2.82M
$1,138,733
28
-4.94%
$3.87M
$41,829
26
-15.60%
$2.19M
$63,749,694
24
-12.24%
$4.33M
$193,112
22
-20.59%
$1.67M
$1,616,354
20
-12.22%
$3.52M
$613,181
18
-20.90%
$3.02M
$960,082
17
-6.29%
$4.34M
Artelo Biosciences, Inc.
(ARTL)
$111,212
12
-28.79%
$3.17M
$139,855
11
-32.84%
$4.05M
$4,146,041
11
-40.86%
$1.31M
$309,830
10
-55.78%
$4.12M
$100,375
8
-51.85%
$3.68M
$159,974
7
-18.60%
$3.57M
$37,465
3
-40.67%
$2.75M
$37,067
3
-89.81%
$3.53M
$552,301
2
-80.60%
$693,249.00
$165,600
2
-3.58%
$3.18M
$739,010
1
3.33%
$3.98M

ARTL Institutional Investors: Active Positions

Increased Positions5+125%52,592+152.36%
Decreased Positions<1-25%525-1.52%
New Positions2New43,094New
Sold Out Positions0Sold Out0Sold Out
Total Postitions8+100%86,586+150.84%

ARTL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Geode Capital Management, Llc$18.000.58%17,35000%2024-12-31
Ubs Group Ag$14.000.44%13,297+13,297New2024-12-31
Tower Research Capital Llc (Trc)$4.000.13%3,818-1,365-26.34%2024-12-31
Bank Of America Corp /De/$0<0.01%2600%2024-12-31
Morgan Stanley$0<0.01%2000%2024-12-31
Rothschild Investment Llc$00%800%2025-03-31

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.